Japanese researchers developing the method highlighted its ability to accurately and rapidly diagnose different strains of malaria in resource-limited endemic regions.
A new assay uses digital loop-mediated isothermal amplification (dLAMP) to perform phenotypic antibacterial susceptibility testing in 30 minutes.
The test leverages loop mediated isothermal amplification technology and enables the rapid detection of Neisseria meningitidis directly from cerebrospinal fluid samples.
Researches are advancing it mainly for use in mosquito surveillance efforts, but also collected data supporting clinical testing of human samples.
The studies provide further support for Meridian's Illumigene Malaria as a tool for routine screening of travelers in non-endemic areas of the world.
The device, which will be tested in collaboration with a Panamanian research institute, will run 40-minute tests without the need for electricity.
The company's net earnings rose, and it reaffirmed its guidance of $195 million to $200 million in revenues for full year 2016.
The LAMP-based test is faster and more sensitive, allowing faster treatment and more accurate diagnosis for malaria patients.
HiberGene will use the funding to develop and commercialize tests for Group B Streptococcus, Clostridium difficile, and norovirus.
The company plans to add assays for Group B Streptococcus, Clostridium difficile, and norovirus in 2016 to complement its existing meningitis test.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.